Lineage Cell Therapeutics (LCTX) Other Accumulated Expenses (2011 - 2023)

Lineage Cell Therapeutics' Other Accumulated Expenses history runs 13 years deep, the most recent figure standing at $1000.0 for Q2 2023.

• In Q2 2023, Other Accumulated Expenses fell 90.0% year-over-year to $1000.0; the TTM figure through Jun 2023 stood at $1000.0 (down 90.0% YoY), while the FY2021 annual figure was $178000.0, up 1877.78% from the prior year.
• Other Accumulated Expenses for Q2 2023 stood at $1000.0, down from $37000.0 in the prior quarter.
• The five-year high for Other Accumulated Expenses was $492000.0 in Q2 2021, with the low at $1000.0 in Q2 2023.
• The 5-year median for Other Accumulated Expenses is $31000.0 (2022), against an average of $78187.5.
• The sharpest annual moves came in 2021 and 2022: Other Accumulated Expenses surged 1877.78% in 2021, then slumped 97.97% in 2022.
• Lineage Cell Therapeutics' Other Accumulated Expenses stood at $4000.0 in 2019, then soared by 125.0% to $9000.0 in 2020, then soared by 1877.78% to $178000.0 in 2021, then tumbled by 85.96% to $25000.0 in 2022, then plunged by 96.0% to $1000.0 in 2023.
• Business Quant data shows LCTX's Other Accumulated Expenses at $1000.0 in Q2 2023, $37000.0 in Q1 2023, and $25000.0 in Q3 2022.